Evidence map›Paper›PMID 32844746›Full record

ArticleeLife2020

Elongation inhibitors do not prevent the release of puromycylated nascent polypeptide chains from ribosomes.

Benjamin D Hobson, Linghao Kong, Erik W Hartwick, Ruben L Gonzalez, Peter A Sims

Open access · goldAbstract read
In one paragraph

Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Translation Dynamics of Single mRNAs in Live Cells.Annual review of biophysics · 2024
    Review
  13. Translation Dynamics of Single mRNAs in Live Cells.Annual review of biophysics · 2024
    Review
  14. Article
  15. Article
  16. Puromycin reveals a distinct conformation of neuronal ribosomes.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  17. Article
  18. Conserved reduction of mProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Benjamin D HobsonDepartment of Systems Biology, Columbia University Irving Medical Center, New York, United States.ORCID 0000-0002-2745-5318
Linghao KongDepartment of Systems Biology, Columbia University Irving Medical Center, New York, United States.
Erik W HartwickDepartment of Chemistry, Columbia University, New York, United States.
Ruben L GonzalezDepartment of Chemistry, Columbia University, New York, United States.ORCID 0000-0002-1344-5581
Peter A SimsDepartment of Systems Biology, Columbia University Irving Medical Center, New York, United States.ORCID 0000-0002-3921-4837
Columbia University Irving Medical Center · USColumbia University · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Large-Scale Integration of Single Cell RNA-Seq and High-Content Imaging for Analyzing Drug Response in CancerR33CA202827 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SIMS, PETER ALAN · 2016 to 2018
$948k
Gene Expression Programs in Maturing Dopamine Neurons: Temporal Regulation, Subcellular Localization, and Alteration by AmphetamineF30DA047775 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HOBSON, BENJAMIN · 2019 to 2023
$239k
NCI NIH HHS P30 CA013696NCI NIH HHS R33 CA202827NIDA NIH HHS F30 DA047775NIH HHS F30 DA047775
6 · The paper itself

Abstract

Puromycin is an amino-acyl transfer RNA analog widely employed in studies of protein synthesis. Since puromycin is covalently incorporated into nascent polypeptide chains, anti-puromycin immunofluorescence enables visualization of nascent protein synthesis. A common assumption in studies of local messenger RNA translation is that the anti-puromycin staining of puromycylated nascent polypeptides in fixed cells accurately reports on their original site of translation, particularly when ribosomes are stalled with elongation inhibitors prior to puromycin treatment. However, when we attempted to implement a proximity ligation assay to detect ribosome-puromycin complexes, we found no evidence to support this assumption. We further demonstrated, using biochemical assays and live cell imaging of nascent polypeptides in mammalian cells, that puromycylated nascent polypeptides rapidly dissociate from ribosomes even in the presence of elongation inhibitors. Our results suggest that attempts to define precise subcellular translation sites using anti-puromycin immunostaining may be confounded by release of puromycylated nascent polypeptide chains prior to fixation.

Indexed as

Protein Synthesis InhibitorsPuromycinRibosomesAnimalsCell Line, TumorMicePeptide Chain Elongation, TranslationalProteinsRNA, MessengerRNA, Transfer, Amino AcylProteinsProtein Synthesis InhibitorsPuromycinRNA, MessengerRNA, Transfer, Amino Acylbiochemistrycell biologychemical biologyhumanlocal translationmouseproximity ligation assaypuromycinribosometranslation

Identifiers

PMID32844746
PMCPMC7490010
OpenAlexW3081121295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.